Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | SMO | Q99835 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16040561 | 0.84 | L3MBTL1 (0.48) | HCRTR2KDM4EALDH1A1ALOX15NPSR1 | |
| SCHEMBL3389125 | 0.83 | KDM4E (0.49) | HCRTR2KDM4ETDP1MAPTALDH1A1 | |
| SCHEMBL264270 | 0.81 | HCRTR2 (0.50) | HCRTR2KDM4EMAPTALDH1A1CYP3A4 | |
| SCHEMBL30775045 | 0.81 | HCRTR2 (0.50) | HCRTR2KDM4EMAPTALDH1A1CYP3A4 | |
| Lithium SCHEMBL607039 | 0.80 | HCRTR2 (0.49) | HCRTR2KDM4EMAPTALDH1A1CYP3A4 | |
| SCHEMBL607037 | 0.80 | HCRTR2 (0.49) | HCRTR2KDM4EMAPTALDH1A1CYP3A4 | |
| SCHEMBL3385678 | 0.77 | KDM4E (0.48) | HCRTR2KDM4EALDH1A1L3MBTL1HCRTR1 | |
| SCHEMBL30775055 | 0.77 | KDM4E (0.48) | HCRTR2KDM4EALDH1A1L3MBTL1HCRTR1 | |
| SCHEMBL2472468 | 0.74 | CYP2A6 (0.53) | KDM4EALDH1A1CYP3A4CYP2A6NPC1 | |
| SCHEMBL31372554 | 0.74 | CYP2A6 (0.53) | KDM4EALDH1A1CYP3A4CYP2A6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105209468-B | Substitution 7 Azabicyclic compounds and they as orexin receptor conditioning agent purposes | 詹森药业有限公司 | 2017-09-08 | — | — | CN | disclosed |
| US-9695183-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-04 | — | — | US | disclosed |
| US-9695183-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-04 | — | — | US | disclosed |
| US-9695183-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-04 | — | — | US | disclosed |
| US-9637496-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-02 | — | — | US | disclosed |
| US-9637496-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-02 | — | — | US | disclosed |
| US-20160376280-A1 | Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376280-A1 | Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | disclosed |
| US-9475819-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-25 | — | — | US | disclosed |
| US-9475819-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-25 | — | — | US | disclosed |
| CN-105209468-A | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| US-20150328224-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-19 | — | — | US | disclosed |
| US-20150328224-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-19 | — | — | US | disclosed |
| US-9062078-B2 | Substituted 7-azabicyles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062078-B2 | Substituted 7-azabicyles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062078-B2 | Substituted 7-azabicyles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| WO-2014159591-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328224-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885KDM4E 1382/4885TDP1 4705/4885 |
| US-20160376280-A1 | Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885KDM4E 1287/4885TDP1 4722/4885 |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885KDM4E 1549/4885TDP1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.